Your browser doesn't support javascript.
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.
Herman, Jonathan D; Wang, Chuangqi; Burke, John Stephen; Zur, Yonatan; Compere, Hacheming; Kang, Jaewon; Macvicar, Ryan; Taylor, Sabian; Shin, Sally; Frank, Ian; Siegel, Don; Tebas, Pablo; Choi, Grace H; Shaw, Pamela A; Yoon, Hyunah; Pirofski, Liise-Anne; Julg, Boris D; Bar, Katharine J; Lauffenburger, Douglas; Alter, Galit.
  • Herman JD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA.
  • Wang C; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Burke JS; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Zur Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Compere H; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Kang J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Macvicar R; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Taylor S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Shin S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Frank I; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Siegel D; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Tebas P; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Choi GH; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.
  • Shaw PA; Biostatistics Unit, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
  • Yoon H; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
  • Pirofski LA; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Julg BD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Bar KJ; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: bark@pennmedicine.upenn.edu.
  • Lauffenburger D; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: lauffen@mit.edu.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: galter@mgh.harvard.edu.
Cell Rep Med ; 3(11): 100811, 2022 Nov 15.
Article in English | MEDLINE | ID: covidwho-2150820
ABSTRACT
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results. Although antibody neutralization is the predominant approach to benchmarking CCP efficacy, CCP may also influence the evolution of the endogenous antibody response. Using systems serology to comprehensively profile severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) functional antibodies of hospitalized people with COVID-19 enrolled in a randomized controlled trial of CCP (ClinicalTrials.gov NCT04397757), we find that the clinical benefits of CCP are associated with a shift toward reduced inflammatory Spike (S) responses and enhanced nucleocapsid (N) humoral responses. We find that CCP has the greatest clinical benefit in participants with low pre-existing anti-SARS-CoV-2 antibody function and that CCP-induced immunomodulatory Fc glycan profiles and N immunodominant profiles persist for at least 2 months. We highlight a potential mechanism of action of CCP associated with durable immunomodulation, outline optimal patient characteristics for CCP treatment, and provide guidance for development of a different class of COVID-19 hyperinflammation-targeting antibody therapeutic agents.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100811

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100811